Extended Disease Control with Unconventional Cabozantinib Dose Increase in Metastatic Renal Cell Carcinoma(1)

BACKGROUND: Cabozantinib is among the most potent tyrosine kinase inhibitors (TKIs) FDA-approved for metastatic renal cell carcinoma (mRCC). Effective treatments after progression on cabozantinib salvage therapy are limited. Dose escalation for other TKIs has been shown to afford added disease contr...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Akanksha, Elias, Roy, Christie, Alana, Williams, Noelle S., Pedrosa, Ivan, Bjarnason, Georg A., Brugarolas, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2022
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894028/
https://www.ncbi.nlm.nih.gov/pubmed/36743424
http://dx.doi.org/10.3233/KCA-210117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894028/
https://www.ncbi.nlm.nih.gov/pubmed/36743424
http://dx.doi.org/10.3233/KCA-210117

Ejemplares similares